All In MedTech

FDA Clearance Tracker · P990025-S069

NAVISTAR

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 9, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 9, 2022

Approved

Time to decision

91 days

Received Jun 10, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class II

The decision

FDA number
P990025-S069
Device name
NAVISTAR
Applicant location
Irvine, CA
Received
Jun 10, 2022
Decided
Sep 9, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P990025

Device type

Device class
Class II
Regulation
21 CFR 870.1220
Specialty
Cardiology

Every decision under product code DRF

FDA's approval statement

As written in FDA's record.

Approval for software and hardware modifications for the nGEN Generator (compatible with the THERMOCOOL, NAVISTAR, and CELSIUS catheters).

Source documents

Other decisions for Biosense Webster, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.